Form 8-K - Current report:
SEC Accession No. 0001437749-25-000109
Filing Date
2025-01-03
Accepted
2025-01-03 07:05:15
Documents
16
Period of Report
2024-12-31
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eton20241219_8k.htm   iXBRL 8-K 28766
2 EXHIBIT 10.1 ASSET PURCHASE AGREEMENT ex_761795.htm EX-10.1 181732
3 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-400 FILING ex_759219.htm EX-99.1 21128
  Complete submission text file 0001437749-25-000109.txt   413405

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eton-20241231.xsd EX-101.SCH 3408
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eton-20241231_def.xml EX-101.DEF 11806
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eton-20241231_lab.xml EX-101.LAB 15857
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eton-20241231_pre.xml EX-101.PRE 12021
18 EXTRACTED XBRL INSTANCE DOCUMENT eton20241219_8k_htm.xml XML 2943
Mailing Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278
Business Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278 (847) 787-7361
Eton Pharmaceuticals, Inc. (Filer) CIK: 0001710340 (see all company filings)

EIN.: 371858472 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38738 | Film No.: 25503740
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)